Explore the vast range of titles available.

Deep neural networks learn from former experiences on a large scale and can be used to predict future disease activity as potential clinical decision support. AdaptiveNet is a novel adaptive recurrent neural network optimized to deal with heterogeneous and missing clinical data. We investigate AdaptiveNet for the prediction of individual disease activity in patients from a rheumatoid arthritis (RA) registry. Demographic and disease characteristics from over 9500 patients and 65.000 visits from the Swiss Quality Management (SCQM) database were used to train and evaluate the network. Patient characteristics, clinical and patient reported outcomes, laboratory values and medication were used as input features. DAS28-BSR served as a target to predict active RA and future numeric individual disease activity by classification and regression. AdaptiveNet predicted active disease defined as DAS28-BSR >2.6 at the next visit with an overall accuracy of 75.6% (SD +- 0.7%) and a sensitivity and specificity of 84.2% (SD +- 1.6%) and 61.5% (SD +- 3.6%), respectively. Prediction performance was significantly higher in patients with a disease duration >3 years and positive rheumatoid factor. Regression allowed forecasting individual DAS28-BSR values with a mean squared error (MSE) of 0.9 (SD +- 0.05). This corresponds to a 8% deviation between estimated and real DAS28-BSR values. Compared to linear regression, random forest and support vector machines, AdaptiveNet showed an increased performance of over 7% in MSE. Medication played a minor role in the prediction of RA disease activity. AdaptiveNet has a superior capacity to predict numeric RA disease activity compared to classical machine learning architectures. All investigated models had limitations in low specificity.

The classification of B cell lymphomas—mainly based on light microscopy evaluation by a pathologist—requires many years of training. Since the B cell receptor (BCR) of the lymphoma clonotype and the microenvironmental immune architecture are important features discriminating different lymphoma subsets, we asked whether BCR repertoire next-generation sequencing (NGS) of lymphoma-infiltrated tissues in conjunction with machine learning algorithms could have diagnostic utility in the subclassification of these cancers. We trained a random forest and a linear classifier via logistic regression based on patterns of clonal distribution, VDJ gene usage and physico-chemical properties of the top-n most frequently represented clonotypes in the BCR repertoires of 620 paradigmatic lymphoma samples—nodular lymphocyte predominant B cell lymphoma (NLPBL), diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL)—alongside with 291 control samples. With regard to DLBCL and CLL, the models demonstrated optimal performance when utilizing only the most prevalent clonotype for classification, while in NLPBL—that has a dominant background of non-malignant bystander cells—a broader array of clonotypes enhanced model accuracy. Surprisingly, the straightforward logistic regression model performed best in this seemingly complex classification problem, suggesting linear separability in our chosen dimensions. It achieved a weighted F1-score of 0.84 on a test cohort including 125 samples from all three lymphoma entities and 58 samples from healthy individuals. Together, we provide proof-of-concept that at least the 3 studied lymphoma entities can be differentiated from each other using BCR repertoire NGS on lymphoma-infiltrated tissues by a trained machine learning model.

Recent advancements in deep learning have shown promise in enhancing the performance of medical image analysis. In pathology, automated whole slide imaging has transformed clinical workflows by streamlining routine tasks and diagnostic and prognostic support. However, the lack of transparency of deep learning models, often described as black boxes , poses a significant barrier to their clinical adoption. This study evaluates various explainability methods for Vision Transformers, assessing their effectiveness in explaining the rationale behind their classification predictions on histopathological images. Using a Vision Transformer trained on the publicly available CAMELYON16 dataset comprising of 399 whole slide images of lymph node metastases of patients with breast cancer, we conducted a comparative analysis of a diverse range of state-of-the-art techniques for generating explanations through heatmaps, including Attention Rollout, Integrated Gradients, RISE, and ViT-Shapley. Our findings reveal that Attention Rollout and Integrated Gradients are prone to artifacts, while RISE and particularly ViT-Shapley generate more reliable and interpretable heatmaps. ViT-Shapley also demonstrated faster runtime and superior performance in insertion and deletion metrics. These results suggest that integrating ViT-Shapley-based heatmaps into pathology reports could enhance trust and scalability in clinical workflows, facilitating the adoption of explainable artificial intelligence in pathology.

Digital biomarkers such as wearables are of increasing interest in monitoring rheumatic diseases, but they usually lack disease specificity. In this study, we apply convolutional neural networks (CNN) to real-world hand photographs in order to automatically detect, extract, and analyse dorsal finger fold lines as a correlate of proximal interphalangeal (PIP) joint swelling in patients with rheumatoid arthritis (RA). Hand photographs of RA patients were taken by a smartphone camera in a standardized manner. Overall, 190 PIP joints were categorized as either swollen or not swollen based on clinical judgement and ultrasound. Images were automatically preprocessed by cropping PIP joints and extracting dorsal finger folds. Subsequently, metrical analysis of dorsal finger folds was performed, and a CNN was trained to classify the dorsal finger lines into swollen versus non-swollen joints. Representative horizontal finger folds were also quantified in a subset of patients before and after resolution of PIP swelling and in patients with disease flares. In swollen joints, the number of automatically extracted deep skinfold imprints was significantly reduced compared to non-swollen joints (1.3, SD 0.8 vs. 3.3, SD 0.49, p < 0.01). The joint diameter/deep skinfold length ratio was significantly higher in swollen (4.1, SD 1.4) versus non-swollen joints (2.1, SD 0.6, p < 0.01). The CNN model successfully differentiated swollen from non-swollen joints based on finger fold patterns with a validation accuracy of 0.84, a sensitivity of 88%, and a specificity of 75%. A heatmap of the original images obtained by an extraction algorithm confirmed finger folds as the region of interest for correct classification. After significant response to disease-modifying antirheumatic drug ± corticosteroid therapy, longitudinal metrical analysis of eight representative deep finger folds showed a decrease in the mean diameter/finger fold length (finger fold index, FFI) from 3.03 (SD 0.68) to 2.08 (SD 0.57). Conversely, the FFI increased in patients with disease flares. In conclusion, automated preprocessing and the application of CNN algorithms in combination with longitudinal metrical analysis of dorsal finger fold patterns extracted from real-world hand photos might serve as a digital biomarker in RA.

Abstract The molecular complexity of cancer presents significant challenges to traditional therapeutic approaches, necessitating the development of innovative treatment strategies capable of addressing the disease’s dynamic nature and resistance mechanisms. Data-driven methodologies, particularly those employing Artificial Intelligence (AI), hold substantial promise by advancing a comprehensive understanding of the intricate molecular and cellular mechanisms underlying cancer and supporting the development of adaptive, patient-specific therapeutic strategies. Initiated through the Mertelsmann Foundation, the Collaborative Research Institute Intelligent Oncology (CRIION) in Freiburg im Breisgau, Germany, aims to drive progress in AI-driven oncology. CRIION fosters global collaboration through initiatives like the Intelligent Oncology Symposium and supports multidisciplinary projects designed to integrate AI innovations into clinical workflows.

Deep neural networks learn from former experiences on a large scale and can be used to predict future disease activity as potential clinical decision support. AdaptiveNet is a novel adaptive recurrent neural network optimized to deal with heterogeneous and missing clinical data. We investigate AdaptiveNet for the prediction of individual disease activity in patients from a rheumatoid arthritis (RA) registry. Demographic and disease characteristics from over 9500 patients and 65.000 visits from the Swiss Quality Management (SCQM) database were used to train and evaluate the network. Patient characteristics, clinical and patient reported outcomes, laboratory values and medication were used as input features. DAS28-BSR served as a target to predict active RA and future numeric individual disease activity by classification and regression. AdaptiveNet predicted active disease defined as DAS28-BSR >2.6 at the next visit with an overall accuracy of 75.6% (SD +- 0.7%) and a sensitivity and specificity of 84.2% (SD +- 1.6%) and 61.5% (SD +- 3.6%), respectively. Prediction performance was significantly higher in patients with a disease duration >3 years and positive rheumatoid factor. Regression allowed forecasting individual DAS28-BSR values with a mean squared error (MSE) of 0.9 (SD +- 0.05). This corresponds to a 8% deviation between estimated and real DAS28-BSR values. Compared to linear regression, random forest and support vector machines, AdaptiveNet showed an increased performance of over 7% in MSE. Medication played a minor role in the prediction of RA disease activity. AdaptiveNet has a superior capacity to predict numeric RA disease activity compared to classical machine learning architectures. All investigated models had limitations in low specificity.

Deep neural networks learn from former experiences on a large scale and can be used to predict future disease activity as potential clinical decision support. AdaptiveNet is a novel adaptive recurrent neural network optimized to deal with heterogeneous and missing clinical data. We investigate AdaptiveNet for the prediction of individual disease activity in patients from a rheumatoid arthritis (RA) registry. Demographic and disease characteristics from over 9500 patients and 65.000 visits from the Swiss Quality Management (SCQM) database were used to train and evaluate the network. Patient characteristics, clinical and patient reported outcomes, laboratory values and medication were used as input features. DAS28-BSR served as a target to predict active RA and future numeric individual disease activity by classification and regression. AdaptiveNet predicted active disease defined as DAS28-BSR >2.6 at the next visit with an overall accuracy of 75.6% (SD +- 0.7%) and a sensitivity and specificity of 84.2% (SD +- 1.6%) and 61.5% (SD +- 3.6%), respectively. Prediction performance was significantly higher in patients with a disease duration >3 years and positive rheumatoid factor. Regression allowed forecasting individual DAS28-BSR values with a mean squared error (MSE) of 0.9 (SD +- 0.05). This corresponds to a 8% deviation between estimated and real DAS28-BSR values. Compared to linear regression, random forest and support vector machines, AdaptiveNet showed an increased performance of over 7% in MSE. Medication played a minor role in the prediction of RA disease activity. AdaptiveNet has a superior capacity to predict numeric RA disease activity compared to classical machine learning architectures. All investigated models had limitations in low specificity.

Clinical data from electronic medical records, registries or trials provide a large source of information to apply machine learning methods in order to foster precision medicine, e.g. by finding new disease phenotypes or performing individual disease prediction. However, to take full advantage of deep learning methods on clinical data, architectures are necessary that 1) are robust with respect to missing and wrong values, and 2) can deal with highly variable-sized lists and long-term dependencies of individual diagnosis, procedures, measurements and medication prescriptions. In this work, we elaborate limitations of fully-connected neural networks and classical machine learning methods in this context and propose AdaptiveNet, a novel recurrent neural network architecture, which can deal with multiple lists of different events, alleviating the aforementioned limitations. We employ the architecture to the problem of disease progression prediction in rheumatoid arthritis using the Swiss Clinical Quality Management registry, which contains over 10.000 patients and more than 65.000 patient visits. Our proposed approach leads to more compact representations and outperforms the classical baselines.

In advancing the understanding of natural decision-making processes, inverse reinforcement learning (IRL) methods have proven instrumental in reconstructing animal's intentions underlying complex behaviors. Given the recent development of a continuous-time multi-intention IRL framework, there has been persistent inquiry into inferring discrete time-varying rewards with IRL. To address this challenge, we introduce the class of hierarchical inverse Q-learning (HIQL) algorithms. Through an unsupervised learning process, HIQL divides expert trajectories into multiple intention segments, and solves the IRL problem independently for each. Applying HIQL to simulated experiments and several real animal behavior datasets, our approach outperforms current benchmarks in behavior prediction and produces interpretable reward functions. Our results suggest that the intention transition dynamics underlying complex decision-making behavior is better modeled by a step function instead of a smoothly varying function. This advancement holds promise for neuroscience and cognitive science, contributing to a deeper understanding of decision-making and uncovering underlying brain mechanisms.